BR112022013339A2 - KV3 MODULATORS - Google Patents

KV3 MODULATORS

Info

Publication number
BR112022013339A2
BR112022013339A2 BR112022013339A BR112022013339A BR112022013339A2 BR 112022013339 A2 BR112022013339 A2 BR 112022013339A2 BR 112022013339 A BR112022013339 A BR 112022013339A BR 112022013339 A BR112022013339 A BR 112022013339A BR 112022013339 A2 BR112022013339 A2 BR 112022013339A2
Authority
BR
Brazil
Prior art keywords
modulators
compound
formula
relates
related aspects
Prior art date
Application number
BR112022013339A
Other languages
Portuguese (pt)
Inventor
Marasco Agostino
Alvaro Giuseppe
Original Assignee
Autifony Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autifony Therapeutics Ltd filed Critical Autifony Therapeutics Ltd
Publication of BR112022013339A2 publication Critical patent/BR112022013339A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

MODULADORES DE KV3. A invenção refere-se a um composto de fórmula (I) e aspectos relacionados.KV3 MODULATORS. The invention relates to a compound of formula (I) and related aspects.

BR112022013339A 2020-02-06 2020-02-06 KV3 MODULATORS BR112022013339A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2020/050268 WO2021156584A1 (en) 2020-02-06 2020-02-06 Kv3 modulators

Publications (1)

Publication Number Publication Date
BR112022013339A2 true BR112022013339A2 (en) 2022-09-13

Family

ID=69591671

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022013339A BR112022013339A2 (en) 2020-02-06 2020-02-06 KV3 MODULATORS

Country Status (11)

Country Link
EP (1) EP4100402A1 (en)
JP (1) JP2023523501A (en)
KR (1) KR20220139923A (en)
CN (1) CN115066424A (en)
AU (1) AU2020427632A1 (en)
BR (1) BR112022013339A2 (en)
CA (1) CA3169057A1 (en)
CL (1) CL2022002081A1 (en)
IL (1) IL295027A (en)
MX (1) MX2022009702A (en)
WO (1) WO2021156584A1 (en)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2575215T3 (en) 2009-12-11 2016-06-27 Autifony Therapeutics Limited Imidazolidinedione derivatives
EP2649066B1 (en) 2010-12-06 2015-10-21 Autifony Therapeutics Limited Hydantoin derivatives useful as kv3 inhibitors
CN103596943B (en) 2011-06-07 2016-10-12 奥蒂福尼疗法有限公司 Hydantoin derivatives as KV3 inhibitor
GB201209986D0 (en) 2012-06-06 2012-07-18 Autifony Therapeutics Ltd Novel compounds
AU2012349847B2 (en) * 2011-12-06 2017-02-16 Autifony Therapeutics Limited Hydantoin derivatives useful as Kv3 inhibitors
US9422252B2 (en) 2012-05-22 2016-08-23 Autifony Therapeutics Limited Triazoles as Kv3 inhibitors
WO2013175211A1 (en) 2012-05-22 2013-11-28 Autifony Therapeutics Limited Hydantoin derivatives as kv3 inhibitors
WO2013182851A1 (en) * 2012-06-06 2013-12-12 Autifony Therapeutics Limited Prophylaxis or treatment of diseases where a modulator of kv3.3 channels is required
GB201521751D0 (en) 2015-12-10 2016-01-27 Autifony Therapeutics Ltd Novel uses
GB201522179D0 (en) 2015-12-16 2016-01-27 Autifony Therapeutics Ltd Novel compounds
GB201613163D0 (en) 2016-07-29 2016-09-14 Autifony Therapeutics Ltd Novel compounds
WO2018109484A1 (en) 2016-12-16 2018-06-21 Autifony Therapeutics Limited Hydantoin modulators of kv3 channels
US20220040163A1 (en) 2018-09-21 2022-02-10 Bionomics Limited Substituted-pyridinyl compounds and uses thereof
IL282096B1 (en) * 2018-10-16 2024-03-01 Autifony Therapeutics Ltd DERIVATIVES OF 3-[5-[(3,3-dialkyl-2H-benzofuran-4-yl]oxy]pyrazin-2-yl]-(5,5-dialkyl-imidazolidine-2,4-dione-and pharmaceutical composition comprising them
AU2019296526A1 (en) 2019-03-25 2021-09-16 Bionomics Limited Substituted-N-heteroaryl compounds and uses thereof

Also Published As

Publication number Publication date
JP2023523501A (en) 2023-06-06
KR20220139923A (en) 2022-10-17
CN115066424A (en) 2022-09-16
AU2020427632A1 (en) 2022-08-18
MX2022009702A (en) 2022-09-07
CA3169057A1 (en) 2021-08-12
WO2021156584A1 (en) 2021-08-12
CL2022002081A1 (en) 2023-05-26
IL295027A (en) 2022-09-01
EP4100402A1 (en) 2022-12-14

Similar Documents

Publication Publication Date Title
MD3864003T2 (en) Prodrug modulators of the integrated stress pathway
EA202092451A1 (en) CONNECTIONS
MX2020004534A (en) Modulators of the integrated stress pathway.
MX2020004538A (en) Modulators of the integrated stress pathway.
EA202091576A1 (en) CONNECTIONS
PH12020500655A1 (en) Compounds
BR112022008294A2 (en) PRODrug COMPOSITIONS AND TREATMENT METHODS
BR112015031293A2 (en) polytiol, composition for optical materials, optical material, and lens
MX2021004386A (en) Novel compounds.
BR112021023144A2 (en) Oxathiazine compounds to inhibit gapdh
CO2024001143A2 (en) Insecticide mixtures
ECSP21088515A (en) PYRROLIDINE COMPOUNDS
BR112023001471A2 (en) PHARMACEUTICAL COMPOSITION OF ANTI-PD-1 ANTIBODY AND ITS USE
BR112022013339A2 (en) KV3 MODULATORS
CL2020002128A1 (en) Herbicidal composition comprising at least one phenolic active compound
EA202192388A1 (en) COMPOSITION AGAINST MICROBIOTES FOR PERCUTANEOUS APPLICATION
EA202190989A1 (en) A NEW METHOD FOR THE SYNTHESIS OF PIPERAZINYL-ETHOXY-BROMPHENYL DERIVATIVES AND THEIR APPLICATION IN THE PREPARATION OF THEIR COMPOUNDS
BR112022012971A2 (en) INSECTICIDE MIXTURES
BR112022006250A2 (en) Aryl heterobicyclic compounds as kv1.3 potassium stirrer channel blockers
MX2021009261A (en) Fluorovinylbenzamide compound as pd-l1 immunomodulator.
MX2020012747A (en) Uracil compound and use thereof.
EA202090888A1 (en) A COMPOUND WITH AN ERK KINASE INHIBITION ACTIVITY AND ITS APPLICATION
BR112019024708A2 (en) delayed-release pharmaceutical compositions
CO2022009260A2 (en) Ophthalmic pharmaceutical compositions
MX2023002525A (en) Novel compounds.